Request Demo
Last update 09 Aug 2025
Navivumab
Last update 09 Aug 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms CT P23, CT P27, CT-P23 + [1] |
Target |
Action modulators |
Mechanism hemagglutinin modulators(Influenza virus hemagglutinin glycoproteins modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9053374L
Source: *****
Sequence Code 316784540H
Source: *****
Related
4
Clinical Trials associated with NavivumabKCT0002211
A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects with Acute Uncomplicated Influenza A Infection
NCT03511066
A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects With Acute Uncomplicated Influenza A Infection
NCT02071914
A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model
100 Clinical Results associated with Navivumab
Login to view more data
100 Translational Medicine associated with Navivumab
Login to view more data
100 Patents (Medical) associated with Navivumab
Login to view more data
100 Deals associated with Navivumab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Influenza A virus infection | Phase 2 | United Kingdom | 15 Feb 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 228 | (CT-P27 90 mg/kg) | ochyokcegd(abrxcetqmk) = fbvzyrczdb vfjauvckjq (qhehmlyqvh, ynrekttwel - uleztlktyr) View more | - | 31 Oct 2022 | ||
(CT-P27 45mg/kg) | ochyokcegd(abrxcetqmk) = yqmanjxqob vfjauvckjq (qhehmlyqvh, aubemagkwc - xsajpupodz) View more | ||||||
Phase 2 | 81 | (CT-P27 10mg/kg) | aoghgdyddt(uvjhetczft) = wdtiktrlod scixpsmgwy (dreajjpgvp, 9.0090) View more | - | 16 Mar 2020 | ||
(CT-P27 20mg/kg) | aoghgdyddt(uvjhetczft) = zqzfbrscbh scixpsmgwy (dreajjpgvp, 9.0817) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free